reports
Form 8.3 - The Vanguard Group, Inc.: Spirent Communications plc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Spirent Communications plc 09-May-2024 / 13:53 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the t...
Form 8.3 - The Vanguard Group, Inc.: BHP Group Limited
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: BHP Group Limited 09-May-2024 / 13:51 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s)...
Form 8.3 - The Vanguard Group, Inc.: UK Commercial Property REIT Limit...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: UK Commercial Property REIT Limited 09-May-2024 / 13:54 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a tru...
Form 8.3 - The Vanguard Group, Inc.: Barratt Developments plc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Barratt Developments plc 09-May-2024 / 13:52 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tru...
LPL Financial Welcomes Advisor Chris Kitaeff
LPL Financial Welcomes Advisor Chris Kitaeff SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- announced today that financial advisor Chris Kitaeff, CPFA, MBA, has joined LPL Financial’s broker-dealer, RIA and custodial platforms. With the move to LPL, Kitaeff joins as a managing director. He reported serving approximately $385 million in advisory, brokerage and retirement plan assets* and joins LPL from Merrill Lynch. Kitaeff is a second-generation advisor who fell in love with wealth management at a young age and followed his father’s footsteps into the industry. He started his career on W...
Next Biometrics Group ASA: 1 director
A director at Next Biometrics Group ASA sold after exercising options/bought 200,000 shares at 8.530NOK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's...
The ODP Corporation Renews and Extends Existing Asset-Based Credit Fac...
BOCA RATON, Fla.--(BUSINESS WIRE)-- The ODP Corporation (NASDAQ:ODP) (“ODP,” or the “Company”), a leading provider of business services, products and digital workplace technology solutions to businesses and consumers, today announced that it has amended and extended its existing asset-based credit facility. The amendment extends the maturity date to May 2029. The renewed $800 million facility includes certain more attractive credit terms and conditions, enhancing the company’s balance sheet and liquidity position to support future growth. “The extension of our credit facility is a validation...
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May ...
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a to discuss the Company’s Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by diali...
National Australia Bank Limited: 1 director
A director at National Australia Bank Limited bought 4,380 shares at 34.000AUD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
GXO meldet Ergebnisse für das erste Quartal 2024
GXO meldet Ergebnisse für das erste Quartal 2024 Umsatz im ersten Quartal von 2,5 Mrd. USD, 6 % mehr als im Vorjahr; organisches Umsatzwachstum1 von 1 %Neue Geschäftsabschlüsse mit einem Jahresumsatz von ca. 250 Mio. USD im 1. Quartal 2024; Anstieg um 55 % im JahresvergleichVerkaufspipeline erreicht 12-Monats-Hoch von 2,2 Mrd. USDAbschluss der Übernahme von Wincanton am 29. April 2024 GREENWICH, Connecticut, May 09, 2024 (GLOBE NEWSWIRE) -- (NYSE: GXO) hat heute die Ergebnisse für das erste Quartal 2024 bekanntgegeben. Malcolm Wilson, Chief Executive Officer von GXO, dazu: „Wir...
GXO publie ses résultats pour le premier trimestre 2024
GXO publie ses résultats pour le premier trimestre 2024 Chiffre d’affaires arrêté à 2,5 milliards de dollars, soit une hausse de 6 % par rapport à l’année précédente ; et croissance organique1 de 1 %Nouveaux contrats signés pour une valeur de près de 250 millions de dollars de chiffre d’affaires annualisé, soit une progression de 55 % par rapport au premier trimestre 2023Prévisions commerciales à 12 mois de l’ordre de 2,2 milliards de dollarsAcquisition finalisée de Wincanton le 29 avril 2024 GREENWICH, État du Connecticut, 09 mai 2024 (GLOBE NEWSWIRE) -- (NYSE : GXO) publie ce jour ses...
- Jonathan Chaplin
SATS: model update
This note covers updates to the model following consolidated EchoStar results. We increased service revenue and EBITDA. Our free cash flow is up very modestly. The company has five to seven months to raise capital. We updated our valuation to $95 / share. We will have another update out once we get the Dish, DBS & Hughes 10-Qs.
CompoSecure Announces Pricing of Secondary Offering of Shares of Class...
CompoSecure Announces Pricing of Secondary Offering of Shares of Class A Common Stock by Selling Shareholders SOMERSET, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- (“CompoSecure”) (Nasdaq: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced the pricing of a secondary offering of 7,000,000 shares of its Class A common stock, par value $0.0001 per share, by certain shareholders of the Company (the “Selling Shareholders”) at a price to the public of $6.50 per share for total gross proceeds of $45,500,000 million (the “Offering”). In connection with the...
Outlook Therapeutics® to Report Financial Results for Second Quarter F...
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it will report its financial results for second quarter fiscal year 2024 on Thursday, May 16, 2024. Outlook Therapeutics management will host its inaugur...
Trelleborg AB: 1 director
A director at Trelleborg AB bought 1,600 shares at 36.084USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Bank Ozk: 1 director
A director at Bank Ozk sold 5,875 shares at 47.950USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Eurohold Bulgaria AD: 1 director
A director at Eurohold Bulgaria AD bought 775,000 shares at 0.930BGN and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
UCB SA: 2 directors
Two Directors at UCB SA sold/bought 1,385 shares at 128.760USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
C I Capital Holding For Financial Investments: 1 director
A director at C I Capital Holding For Financial Investments bought 342,000 shares at 0.000EGP and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
Gamuda Berhad: 1 director
A director at Gamuda Berhad sold 60,000 shares at 5.450MYR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.